{"name":"Li-kun Chen","slug":"li-kun-chen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Administration of Vorolanib","genericName":"Administration of Vorolanib","slug":"administration-of-vorolanib","indication":"Advanced or metastatic solid tumors (Phase 2 investigation)","status":"phase_2"}]}],"pipeline":[{"name":"Administration of Vorolanib","genericName":"Administration of Vorolanib","slug":"administration-of-vorolanib","phase":"phase_2","mechanism":"Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth.","indications":["Advanced or metastatic solid tumors (Phase 2 investigation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5vR0xhTnZ6bzU3M050S1BxMmRTZ3pVRUVqU2xUYTQyNzd0bVAyR0N4ZEdSNkREU01oMjc3d0FZWUVHS21aUkdKOWFJTFhwVXhVck1EdHVPX0hMa3NwRWlTZ25jRkFyLU43QWVUb041SVR4NlluY1ByVE5zUWM?oc=5","date":"2025-09-26","type":"pipeline","source":"Law.asia","summary":"Global Law Office adds pharmaceuticals and financing trio | China - Law.asia","headline":"Global Law Office adds pharmaceuticals and financing trio | China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9CTFFEbnBnOXNkZnVJQS00VXgyNnBGWEV5ZXFiYTEzbXpxQnV1UDktRmlQaGN0M1NWWnloQV92VF9xV3IwYWZaenhEZlRXWnAyc0EteWJoeGVOcHdFazVpdUhHb01BRG1yTFlN?oc=5","date":"2025-07-18","type":"deal","source":"Law.asia","summary":"Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy - Law.asia","headline":"Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ycTcwN25vT2FIZkVWV3VfcHB4b29nd2tSSHNFc210emktcDRKdXVaSzlDSzZNS0locTBLOW8ybmV4WE84WGM1aThVS0hncHhwVi1XQ29zYVFJSGlQbFpF?oc=5","date":"2024-11-08","type":"pipeline","source":"中山大学","summary":"Schools Hold Graduation Ceremonies and Degree Ceremonies (1) - 中山大学","headline":"Schools Hold Graduation Ceremonies and Degree Ceremonies (1) - 中山大学","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1zdWFvZ01lV2tkNHB6VkRaN2xHNVVOUS1YbGxEbnlGRTZVQmNoZ2VXc1Iyd3dUdlhBcDA2MG5IRXdaM1VhZEYwNHo5NHk1UFBsWlNvNnA3V0pLNXdoM2Rr?oc=5","date":"2024-01-29","type":"trial","source":"nature.com","summary":"QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study - nature.com","headline":"QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung ca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5DSW5BU1cwbWZldFdQV3lvSnpydUhUNUhTTi1vNUcxV0ZQcjJIc1RhZ0xLbFJwUWh5cUdOdGVyeTJPRk1meVFuWXFsYWQ2dXF1cTZaOENDTnR6NTNRbUdn?oc=5","date":"2020-08-05","type":"pipeline","source":"nature.com","summary":"Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients | Cell Discovery - nature.com","headline":"Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5qWWZ2ZUh5aW5xNmJUd05XX1NZYS1CamFBRWR4SmJfbWotV1BTTDE5SjRnMTgwTWgwQU5ERnQyVkgwN3lXR1hrcmhDOGlULW5TcDExMWNNNnMxQ2M1aUVGV25IZ25YbW9f0gFoQVVfeXFMT3pWR09xbV9RaEpsVGNETlV5b0wwbGljN0F2bzJidktvcFVoOXplMGVJMTBGaW5mU2R6UExFSGNnaXE4VUtueWF2MTdZRFhJMi02MlF2REVhbjJQWE13QnY4OU9vdlRNTTI?oc=5","date":"2019-03-27","type":"pipeline","source":"The State","summary":"Knox Abbott Drive business sells for $6 million - The State","headline":"Knox Abbott Drive business sells for $6 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE54eEJPcHdCeEVxeTluMW1ya1ZCMkRSbll3cGV0TnNLVXBoM1NrM2V5ZjNhSE1oZk9BZUY5MWdtQWRqTGZDVDI1M1NwV1p4ZFk4eDcwdw?oc=5","date":"2017-03-17","type":"pipeline","source":"nature.com","summary":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo - nature.com","headline":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE52VWVScjM1THFfSy0yaDk2M1VsLXhZRzlyQjBvRVEyTVpURlQ5WVptY3BJeEhDYWdEZEhmbnp2Z0FleUxuUndxWTZoaHp6dlEzdmxJ?oc=5","date":"2016-08-17","type":"pipeline","source":"nature.com","summary":"Controlled release of liraglutide using thermogelling polymers in treatment of diabetes - nature.com","headline":"Controlled release of liraglutide using thermogelling polymers in treatment of diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9SY3g3eWluZkFOWGVZYjh4em5EOVd1THZ1OGk2a25tM3R6WFVYSzBCakpuOUpTcnZMUlF3Y05vT0N3S2JUdVMtbzdCeHZfYW5fTFV5NA?oc=5","date":"2012-10-22","type":"pipeline","source":"nature.com","summary":"Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling - nature.com","headline":"Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}